Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3
The oncogenic microRNA-21 contributes to the pathogenesis of multiple myeloma. Ibrutinib (also referred to as PCI-32765), an inhibitor of Bruton’s tyrosine kinase, while its effects on multiple myeloma have not been well described. Here, we show that microRNA-21 is an oncogenic marker closely linked...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IOS Press
2018-01-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317731369 |